Evidence map›Paper›PMID 27519221›Full record

ArticleEndocrine pathology1999

Proliferative activity of oxyphilic (Hurthle) cells in reactive and neoplastic thyroid lersions.

M S Tretiakova, M Papotti, G Bussolati

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

M S TretiakovaDepartment of Pathology, St. Petersburg State Medical, Academy, Russia.
M PapottiDepartment of Biomedical Sciences and Human Oncology, University of Turin, Via Santena 7, I-10126, Torino, Italy.
G BussolatiDepartment of Biomedical Sciences and Human Oncology, University of Turin, Via Santena 7, I-10126, Torino, Italy. bussola@molinette.unito.it.
University of Turin · ITSaint Petersburg State Pediatric Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The proliferative potential of oxyphilic (Hurthle) cells (HCs) present in neoplastic and non-neoplastic thyroid lesions is uncertain. To estimate the HCs ability to proliferate and to determine whether their proliferative activity correlates with the biologic behavior of different thyroid oxyphilic lesions, we selected 31 cases of chronic lymphocytic (Hashimoto's) thyroiditis and 28 oxyphilic (Hurthle cell) thyroid tumors, including 12 adenomas and 16 carcinomas. Seven histologically normal thyroid specimens from euthyroid patients served as control tissue. The proliferative activity of HCs was evaluated by means of a double immunostaining for Ki67 and a mitochondrial antigen (which specifically recognizes oxyphilic cells). Oxyphilic cells in thyroiditis had a low proliferative activity (PA: 0.55%), although higher than that of normal thyroid parenchyma (PA: 0.06%). Neoplastic HC lesions had a mean proliferative activity of 1.56% and 6.26% in adenomas and carcinomas, respectively. A statistically significant difference was observed between proliferative activity of non-neoplastic and neoplastic lesions (p<0.01), but not within the tumor group, between adenomas and carcinomas. In addition, HC carcinomas had a statistically significant positive correlation between proliferative activity and tumor size (p<0.01) and the presence of necrosis (p<0.001).

Indexed as

immunohistochemistryKi67mitochondrion-rich cellsoxyphilic (Hurthle) cellsproliferationThyroid

Identifiers

PMID27519221
OpenAlexW1981278065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.